Targovax ASA appoints Dr Victor Levitsky as Chief Scientific Officer
Oslo, Norway, 30 April 2020 - Targovax ASA (OSE: TRVX) announces the appointment of Dr Victor Levitsky, MD, PhD as Chief Scientific Officer (CSO). He will play a leading role in driving research strategy and pipeline expansions, particularly the scientific and mechanistic aspects of early clinical work. Dr Levitsky will serve as a member of Targovax’s management team. Dr Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development.